Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq

Lichen International Limited (NASDAQ: LICN), a Chinese financial and taxation services provider rather than a pharma or biotech firm, priced a registered direct offering of 17.5 million units at $0.20 each. Each unit has one Class A share (or a pre-funded warrant) and a warrant for 4.72 shares exercisable at $0.20 for one year. Gross proceeds are about $3.5 million, with closing expected November 11, 2026 under an effective Form F-3 shelf, and Univest Securities is the sole placement agent.

12 Nov 2026 · Lichen International Ltd LICN · Company news

Company's press release (SEC filing): Lichen International Ltd ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Tenon Medical Q3 2026 revenue up 22% to $1.4M; convertible notes repaid after $15.6M raised